drugset
drugset / Trial / NCT00004409

Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease

NCT00004409 ↗

Phase 2 Completed 36 enrolled State University of New York
RandomizedDouble-blindTreatment

Summary

OBJECTIVES: Evaluate the safety and efficacy of collagenase in improving flexion deformity, range of motion, and grip strength in patients with residual Dupuytren's disease.

Timeline

Start
1995-08
Primary completion
—
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic — Other

Indications

palmar fibromatosis